D866E

Category 3/4 — Most DruggableUncertain significanceLumenal · predictedσ-1 candidateSource card

Aspartic acid → Glutamic acid at position 866 · C-terminal ER-lumenal (calcium binding, calmodulin, chaperone) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference

Wild-type D866 — ionic bond to K862

Fullscreen ↗

DynaMut2 mutant · D866E

Mutant E866 — ionic bond to K862 lost (4 contacts lost)

Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

4 lost0 gained7 preserved

Interaction type	Wild-type partner	Mutant partner	Status
Ionic bond	K862	—	Lost
Hydrogen bond	K862	—	Lost
Hydrogen bond	E864	E864	Preserved
Hydrogen bond	S869	S869	Preserved
Hydrogen bond	T870	T870	Preserved
Polar contact	K862	—	Lost
Polar contact	E864	E864	Preserved
Polar contact	R868	—	Lost
Polar contact	S869	S869	Preserved
Polar contact	T870	T870	Preserved
Van der Waals	R868	R868	Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG

-0.49kcal/mol

Destabilising — mild

AlphaMissense

0.606

likely pathogenic

AlphaFold pLDDT

model confidence

Schema

Cat 3/4

Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance

Review statuscriteria provided, single submitter

Associated conditions—

Population frequency (gnomAD v4)Ultra-rare · AF 0.00027%

cDNA changec.2598C>G

ClinVar accessionVCV001517598

Last evaluated2025/04/16 00:00

Observed at very low frequency in gnomAD.

Full Variant Card

WFS1 Wolframin — D866E Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Aspartic acid → Glutamic acid at position 866. C-terminal ER-lumenal (calcium binding. ClinVar Uncertain significance, AlphaMissense 0.606, DynaMut2 ΔΔG -0.49 kcal/mol (destabilising).

Identity

Field	Value
Variant	D866E (p.Aspartic acid866Glutamic acid)
DNA change	c.2598C>G
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV001517598
Amino acid change	Aspartic acid (D) → Glutamic acid (E)

Structural Context

Field	Value
AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 866	63.50 — confident
Domain	C-terminal ER-lumenal (calcium binding, calmodulin, chaperone)
Position context	C-terminal lumenal domain · position 866 projects into the ER lumen
IDR flag	No — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 866 sits in the C-terminal lumenal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na+/K+ ATPase β1. The wild-type residue is negatively charged (aspartate — carboxylate); the mutant is negatively charged (glutamate — carboxylate). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

Computational Predictions

AlphaMissense

Field	Value
am_pathogenicity	0.6064
am_class	likely pathogenic
Interpretation	Likely pathogenic (threshold 0.564)

DynaMut2

Field	Value
ΔΔG (kcal/mol)	-0.49 (Destabilising)
Job ID	178092131995
Result URL	https://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092131995

Clinical Evidence

Field	Value
Classification	Uncertain significance
Review status	criteria provided, single submitter
Last evaluated	2025/04/16 00:00
Inheritance	Inheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscape	D866E is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

(no conditions catalogued)

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=0.49 < 2 kcal/mol (fold intact) + AlphaMissense 0.606 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.49 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.606. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.

Files in this folder

AF-O76024-F1-model_v6.pdb — AlphaFold structure
D866E_molstar_viewer.html — interactive 3D viewer (auto-highlights position 866 with ball-and-stick + neighbors within 5Å)
D866E_variant_card.md — this card (source of truth)
D866E_variant_card.html — styled printable card
D866E_dynamut2_summary.html — clean offline DynaMut2 result card
dynamut2_result.json — structured result data
dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
D866E_wildtype_interactions.pse / D866E_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the D866E PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download D866E PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.